NIMBLE Trial Shows Significant Efficacy of Cemdisiran for gMG
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy REGN?
Source: Newsfilter
- Significant Efficacy: The NIMBLE trial demonstrated that patients treated with cemdisiran showed a 4.5-point improvement in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score at week 24 compared to a 2.2-point improvement in the placebo group, indicating cemdisiran's potential best-in-class efficacy in improving daily functions for gMG patients.
- Rapid Improvement: Among patients receiving cemdisiran, 76.6% achieved a ≥3-point improvement, compared to only 44.1% in the placebo group, highlighting cemdisiran's ability to significantly enhance patient quality of life in a short timeframe, addressing the urgent need for effective treatments.
- Good Safety Profile: In the NIMBLE trial, 69.2% of cemdisiran patients experienced treatment-emergent adverse events (AEs), most of which were mild to moderate, and there were no treatment discontinuations due to AEs through week 24, demonstrating cemdisiran's favorable tolerability.
- Regulatory Application Submitted: Regeneron submitted a regulatory application for cemdisiran to U.S. authorities in Q1 2026, and if approved, it will become the first siRNA therapy for gMG, marking a significant advancement in this therapeutic area.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 746.580
Low
637.00
Averages
808.50
High
1057
Current: 746.580
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sanofi Q1 Results Exceed Market Expectations
- Strong Performance: Sanofi reported total sales of €10.51 billion ($12.29 billion) for Q1, surpassing analyst expectations of €10.22 billion, indicating robust market performance that is likely to boost investor confidence.
- Profit Growth: Quarterly business operating income reached €2.97 billion ($3.47 billion), exceeding the average analyst estimate of €2.85 billion, reflecting significant progress in cost control and operational efficiency.
- Dupixent Sales Surge: Sales of Dupixent rose by 30.8% to €4.17 billion ($4.88 billion), far exceeding analysts' expectations of €3.89 billion, demonstrating sustained demand for the drug in asthma and eczema treatment, thereby reinforcing Sanofi's market position.
- Executive Transition Impact: Following the ousting of former CEO Paul Hudson due to failure to revitalize the drug pipeline, new CEO Belén Garijo is set to take over at the end of April, which may lead to strategic shifts affecting future R&D and market strategies.
See More
FDA Approves Dupixent for Treatment of CSU in Children Aged 2 to 11
- New Treatment Option for Children: Dupixent (dupilumab) has received FDA approval as the first biologic for chronic spontaneous urticaria (CSU) in children aged 2 to 11, addressing a significant treatment gap and expected to greatly enhance their quality of life.
- Clinical Trial Support: The approval is primarily based on data from the LIBERTY-CUPID clinical trial program, demonstrating Dupixent's efficacy in reducing itch severity and urticaria activity, particularly in patients aged 12 and older, thereby enhancing its applicability in younger populations.
- Strong Market Demand: Over 14,000 children aged 2 to 11 in the U.S. suffer from uncontrolled CSU symptoms, and Dupixent's approval provides a new treatment avenue for these patients, likely driving growth in the pediatric allergy treatment market.
- Strategic Implications: With approvals for nine allergy-related conditions, the FDA's authorization reinforces Dupixent's established safety and efficacy profile, potentially transforming treatment paradigms for chronic diseases and strengthening Regeneron and Sanofi's competitive position in the biologics market.
See More
Sanofi Reports Strong Q1 Results Driven by Dupixent Sales
- Revenue Growth: Sanofi reported first-quarter sales of €10.51 billion, exceeding analyst expectations of €10.22 billion, indicating strong market performance that is likely to boost investor confidence.
- Operating Income Increase: The company’s operating income for the first quarter reached €2.97 billion, surpassing the forecast of €2.85 billion, reflecting robust growth in its core business that may enhance future shareholder returns.
- Strong Dupixent Sales: Sales of Dupixent surged 30.8% year-over-year to €4.17 billion, comfortably beating analysts' forecast of €3.89 billion, demonstrating sustained strong demand for the drug in asthma and eczema treatment.
- Vaccine Division Performance: The vaccines division generated sales of €1.3 billion, with solid demand for polio and pertussis vaccines offsetting weaker sales of flu and RSV shots, indicating stability in the company's vaccine market.
See More
Dupixent Approved for Young Children with Chronic Urticaria
- Pediatric Indication Expansion: Sanofi and Regeneron's Dupixent has been approved in the U.S. as the first biologic for children aged 2 to 11 with uncontrolled chronic spontaneous urticaria (CSU), marking a significant expansion in its pediatric indications that is expected to substantially boost market demand and company revenues.
- Clinical Research Support: The approval is primarily based on data from the LIBERTY-CUPID clinical study program, demonstrating Dupixent's efficacy in children who remain symptomatic despite H1 antihistamine treatment, thereby reinforcing its position in the chronic skin disease treatment landscape and enhancing the company's competitive edge in the biopharmaceutical market.
- Safety Consistency: Safety results from all four CSU studies were generally consistent with Dupixent's known safety profile in its approved dermatological indications, with no new adverse reactions identified in children aged 2 to 11, ensuring market acceptance and physician trust in the product.
- Significant Market Potential: Dupixent is now approved for five diseases driven in part by type 2 inflammation in children, and with the rising number of pediatric CSU patients, it is projected to generate substantial long-term revenue for Sanofi and Regeneron, further solidifying their leadership in the pediatric biologics market.
See More
Dupixent Approved for Children with Chronic Spontaneous Urticaria
- First Biologic Approval: Dupixent (dupilumab) has become the first biologic approved in the US for children aged 2 to 11 with chronic spontaneous urticaria (CSU), addressing a significant treatment gap and is expected to greatly enhance the quality of life for affected children.
- Clinical Study Support: The approval is primarily based on data from the LIBERTY-CUPID clinical study program, demonstrating that Dupixent significantly reduced itch severity and urticaria activity over 24 weeks, confirming its efficacy and safety in pediatric patients.
- Significant Market Potential: Over 14,000 children aged 2 to 11 in the US suffer from CSU that remains uncontrolled despite H1 antihistamine treatment, and Dupixent's approval provides a new therapeutic option that could transform their treatment landscape.
- Multiple Indication Expansion: Dupixent is now approved for nine different allergy-related conditions, marking the fifth indication extended to children, further solidifying its critical role in managing chronic diseases driven by type 2 inflammation.
See More
Investment Opportunities in Biotech Stocks
- Moderna's Innovative Potential: Moderna's mRNA vaccine platform allows for faster vaccine design compared to traditional methods, which could drive long-term returns, especially given the increased uncertainty in the COVID-19 vaccine market, where the company's deep pipeline and innovative technology may yield significant investment returns.
- Diverse Pipeline Products: Moderna is developing a vaccine for norovirus and a personalized cancer vaccine, mRNA-4157, which has shown significant potential in mid-stage trials to reduce recurrence and death risk in melanoma patients, further enhancing its market competitiveness.
- Regeneron's Market Leadership: Regeneron's Dupixent is a top-selling drug globally, particularly after gaining important label expansions for COPD treatment, expected to continue driving sales growth, while its high-dose Eylea offers a more patient-friendly dosing regimen, attracting patients despite biosimilar competition.
- Diversified Product Pipeline: Regeneron is developing products across various therapeutic areas, including gene therapy for genetic deafness and anti-obesity medications, which, if approved, could boost revenue and earnings, while its dividend and share buyback program demonstrate a commitment to returning capital to shareholders.
See More
Sanofi Q1 Results Exceed Market Expectations
- Strong Performance: Sanofi reported total sales of €10.51 billion ($12.29 billion) for Q1, surpassing analyst expectations of €10.22 billion, indicating robust market performance that is likely to boost investor confidence.
- Profit Growth: Quarterly business operating income reached €2.97 billion ($3.47 billion), exceeding the average analyst estimate of €2.85 billion, reflecting significant progress in cost control and operational efficiency.
- Dupixent Sales Surge: Sales of Dupixent rose by 30.8% to €4.17 billion ($4.88 billion), far exceeding analysts' expectations of €3.89 billion, demonstrating sustained demand for the drug in asthma and eczema treatment, thereby reinforcing Sanofi's market position.
- Executive Transition Impact: Following the ousting of former CEO Paul Hudson due to failure to revitalize the drug pipeline, new CEO Belén Garijo is set to take over at the end of April, which may lead to strategic shifts affecting future R&D and market strategies.
See More
FDA Approves Dupixent for Treatment of CSU in Children Aged 2 to 11
- New Treatment Option for Children: Dupixent (dupilumab) has received FDA approval as the first biologic for chronic spontaneous urticaria (CSU) in children aged 2 to 11, addressing a significant treatment gap and expected to greatly enhance their quality of life.
- Clinical Trial Support: The approval is primarily based on data from the LIBERTY-CUPID clinical trial program, demonstrating Dupixent's efficacy in reducing itch severity and urticaria activity, particularly in patients aged 12 and older, thereby enhancing its applicability in younger populations.
- Strong Market Demand: Over 14,000 children aged 2 to 11 in the U.S. suffer from uncontrolled CSU symptoms, and Dupixent's approval provides a new treatment avenue for these patients, likely driving growth in the pediatric allergy treatment market.
- Strategic Implications: With approvals for nine allergy-related conditions, the FDA's authorization reinforces Dupixent's established safety and efficacy profile, potentially transforming treatment paradigms for chronic diseases and strengthening Regeneron and Sanofi's competitive position in the biologics market.
See More
Sanofi Reports Strong Q1 Results Driven by Dupixent Sales
- Revenue Growth: Sanofi reported first-quarter sales of €10.51 billion, exceeding analyst expectations of €10.22 billion, indicating strong market performance that is likely to boost investor confidence.
- Operating Income Increase: The company’s operating income for the first quarter reached €2.97 billion, surpassing the forecast of €2.85 billion, reflecting robust growth in its core business that may enhance future shareholder returns.
- Strong Dupixent Sales: Sales of Dupixent surged 30.8% year-over-year to €4.17 billion, comfortably beating analysts' forecast of €3.89 billion, demonstrating sustained strong demand for the drug in asthma and eczema treatment.
- Vaccine Division Performance: The vaccines division generated sales of €1.3 billion, with solid demand for polio and pertussis vaccines offsetting weaker sales of flu and RSV shots, indicating stability in the company's vaccine market.
See More
Dupixent Approved for Young Children with Chronic Urticaria
- Pediatric Indication Expansion: Sanofi and Regeneron's Dupixent has been approved in the U.S. as the first biologic for children aged 2 to 11 with uncontrolled chronic spontaneous urticaria (CSU), marking a significant expansion in its pediatric indications that is expected to substantially boost market demand and company revenues.
- Clinical Research Support: The approval is primarily based on data from the LIBERTY-CUPID clinical study program, demonstrating Dupixent's efficacy in children who remain symptomatic despite H1 antihistamine treatment, thereby reinforcing its position in the chronic skin disease treatment landscape and enhancing the company's competitive edge in the biopharmaceutical market.
- Safety Consistency: Safety results from all four CSU studies were generally consistent with Dupixent's known safety profile in its approved dermatological indications, with no new adverse reactions identified in children aged 2 to 11, ensuring market acceptance and physician trust in the product.
- Significant Market Potential: Dupixent is now approved for five diseases driven in part by type 2 inflammation in children, and with the rising number of pediatric CSU patients, it is projected to generate substantial long-term revenue for Sanofi and Regeneron, further solidifying their leadership in the pediatric biologics market.
See More
Dupixent Approved for Children with Chronic Spontaneous Urticaria
- First Biologic Approval: Dupixent (dupilumab) has become the first biologic approved in the US for children aged 2 to 11 with chronic spontaneous urticaria (CSU), addressing a significant treatment gap and is expected to greatly enhance the quality of life for affected children.
- Clinical Study Support: The approval is primarily based on data from the LIBERTY-CUPID clinical study program, demonstrating that Dupixent significantly reduced itch severity and urticaria activity over 24 weeks, confirming its efficacy and safety in pediatric patients.
- Significant Market Potential: Over 14,000 children aged 2 to 11 in the US suffer from CSU that remains uncontrolled despite H1 antihistamine treatment, and Dupixent's approval provides a new therapeutic option that could transform their treatment landscape.
- Multiple Indication Expansion: Dupixent is now approved for nine different allergy-related conditions, marking the fifth indication extended to children, further solidifying its critical role in managing chronic diseases driven by type 2 inflammation.
See More
Investment Opportunities in Biotech Stocks
- Moderna's Innovative Potential: Moderna's mRNA vaccine platform allows for faster vaccine design compared to traditional methods, which could drive long-term returns, especially given the increased uncertainty in the COVID-19 vaccine market, where the company's deep pipeline and innovative technology may yield significant investment returns.
- Diverse Pipeline Products: Moderna is developing a vaccine for norovirus and a personalized cancer vaccine, mRNA-4157, which has shown significant potential in mid-stage trials to reduce recurrence and death risk in melanoma patients, further enhancing its market competitiveness.
- Regeneron's Market Leadership: Regeneron's Dupixent is a top-selling drug globally, particularly after gaining important label expansions for COPD treatment, expected to continue driving sales growth, while its high-dose Eylea offers a more patient-friendly dosing regimen, attracting patients despite biosimilar competition.
- Diversified Product Pipeline: Regeneron is developing products across various therapeutic areas, including gene therapy for genetic deafness and anti-obesity medications, which, if approved, could boost revenue and earnings, while its dividend and share buyback program demonstrate a commitment to returning capital to shareholders.
See More
